跳至主要内容
临床试验/CTRI/2023/05/053055
CTRI/2023/05/053055尚未招募Unknown

A prospective pilot study to assess the effect of Resveratrol-Copper on the viral load in patients with Chronic Hepatitis B and C virus infection

Tata Memorial Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age above 18 years
  • -ECOG- performance status of 0 or 1
  • -Chronic HBV infection with HBV DNA levels more than equal to 2000 IU per mL and normal ALT alanine amino transferase
  • These patients are not routinely treated with antivirals due to limited activity. ALT is traditionally considered to be marker of hepatocellular injury. Various studies using interferon, peg interferon, Lamivudine, Adefovir have shown the importance of elevated ALT levels in predicting the response rate to therapy
  • -Chronic HCV infection with detectable HCV RNA levels and Genotype 2 or -who are eligible for antiviral treatment as per standard guidelines
  • -No active malignancy at least 1 year of DFS following successful anticancer Rx
  • -Adequate hepatic, renal, and hematologic function at baseline
  • -Patients who have given written informed consent

排除标准

  • -Age more 60 years
  • -Any other Genotype of HCV
  • -Acute Hepatitis
  • -Cirrhosis
  • -Decompensated chronic liver disease
  • -Concurrent chemotherapy
  • -Current or previous antiviral treatment for HBV or HCV
  • -Coexistent dual infection- i.e. HBV with HCV
  • -Coexistent HIV infection
  • -Uncontrolled medical comorbidities like hypertensive, diabetes mellitus
  • -Patients taking alternative/ complementary treatments

研究者

相似试验